These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26973396)

  • 1. Factors associated with increased incidence of severe toxicities following yttrium-90 resin microspheres in the treatment of hepatic malignancies.
    Roberson Ii JD; McDonald AM; Baden CJ; Lin CP; Jacob R; Burnett Iii OL
    World J Gastroenterol; 2016 Mar; 22(10):3006-14. PubMed ID: 26973396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.
    Piana PM; Gonsalves CF; Sato T; Anne PR; McCann JW; Bar Ad V; Eschelman DJ; Parker L; Doyle LA; Brown DB
    J Vasc Interv Radiol; 2011 Oct; 22(10):1373-9. PubMed ID: 21764600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis.
    Kim AY; Frantz S; Brower J; Akhter N
    J Vasc Interv Radiol; 2019 Mar; 30(3):298-304.e2. PubMed ID: 30819469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe coagulopathy after 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome.
    Hoffman MA; Rubin JI; Vinceguerra VP; Nowakowski FS; Warner RR
    J Vasc Interv Radiol; 2008 Jul; 19(7):1099-102. PubMed ID: 18589326
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis.
    Tsai AL; Burke CT; Kennedy AS; Moore DT; Mauro MA; Dixon RD; Stavas JM; Bernard SA; Khandani AH; O'Neil BH
    J Vasc Interv Radiol; 2010 Sep; 21(9):1377-84. PubMed ID: 20691606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.
    Goin JE; Salem R; Carr BI; Dancey JE; Soulen MC; Geschwind JF; Goin K; Van Buskirk M; Thurston K
    J Vasc Interv Radiol; 2005 Feb; 16(2 Pt 1):205-13. PubMed ID: 15713921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of repeated yttrium-90 radioembolization.
    Lam MG; Louie JD; Iagaru AH; Goris ML; Sze DY
    Cardiovasc Intervent Radiol; 2013 Oct; 36(5):1320-8. PubMed ID: 23354961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients.
    Peterson JL; Vallow LA; Johnson DW; Heckman MG; Diehl NN; Smith AA; Tzou KS; Paz-Fumagalli R; Kim S; Ko SJ; Daugherty LC; Kim GP; Brown N; Mori KW; Buskirk SJ
    Brachytherapy; 2013; 12(6):573-9. PubMed ID: 23953810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience.
    Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R
    Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Same-Day Yttrium-90 Radioembolization: Feasibility with Resin Microspheres.
    Li MD; Chu KF; DePietro A; Wu V; Wehrenberg-Klee E; Zurkiya O; Liu RW; Ganguli S
    J Vasc Interv Radiol; 2019 Mar; 30(3):314-319. PubMed ID: 30819470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.
    Rühl R; Seidensticker M; Peters N; Mohnike K; Bornschein J; Schütte K; Amthauer H; Malfertheiner P; Pech M; Ricke J
    Dig Dis; 2009; 27(2):189-99. PubMed ID: 19546558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of new hepaticoenteric collateral pathways after hepatic arterial skeletonization in preparation for yttrium-90 radioembolization.
    Abdelmaksoud MH; Hwang GL; Louie JD; Kothary N; Hofmann LV; Kuo WT; Hovsepian DM; Sze DY
    J Vasc Interv Radiol; 2010 Sep; 21(9):1385-95. PubMed ID: 20688531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
    Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
    J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction.
    Garwood ER; Fidelman N; Hoch SE; Kerlan RK; Yao FY
    Liver Transpl; 2013 Feb; 19(2):164-73. PubMed ID: 23008091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?
    Gates VL; Hickey R; Marshall K; Williams M; Salzig K; Lewandowski RJ; Salem R
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2038-44. PubMed ID: 26194715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.